Higher Spin Gauge Theories in Any Dimension

Some general properties of higher spin gauge theories are summarized with the emphasize on the nonlinear theories in any dimension.Comment: 15 pages, Proceedings of Strings 2004, Paris, June 28-July

Subexponential estimations in Shirshov's height theorem (in English)

In 1993 E. I. Zelmanov asked the following question in Dniester Notebook: "Suppose that F_{2, m} is a 2-generated associative ring with the identity x^m=0. Is it true, that the nilpotency degree of F_{2, m} has exponential growth?" We show that the nilpotency degree of l-generated associative algebra with the identity x^d=0 is smaller than Psi(d,d,l), where Psi(n,d,l)=2^{18} l (nd)^{3 log_3 (nd)+13}d^2. We give the definitive answer to E. I. Zelmanov by this result. It is the consequence of one fact, which is based on combinatorics of words. Let l, n and d>n be positive integers. Then all the words over alphabet of cardinality l which length is greater than Psi(n,d,l) are either n-divided or contain d-th power of subword, where a word W is n-divided, if it can be represented in the following form W=W_0 W_1...W_n such that W_1 >' W_2>'...>'W_n. The symbol >' means lexicographical order here. A. I. Shirshov proved that the set of non n-divided words over alphabet of cardinality l has bounded height h over the set Y consisting of all the words of degree <n. Original Shirshov's estimation was just recursive, in 1982 double exponent was obtained by A.G.Kolotov and in 1993 A.Ya.Belov obtained exponential estimation. We show, that h<Phi(n,l), where Phi(n,l) = 2^{87} n^{12 log_3 n + 48} l. Our proof uses Latyshev idea of Dilworth theorem application.Comment: 21 pages, Russian version of the article is located at the link arXiv:1101.4909; Sbornik: Mathematics, 203:4 (2012), 534 -- 55

Left ventricular function, congestion, and effect of empagliflozin on heart failure risk after myocardial infarction

Background Empagliflozin reduces the risk of heart failure (HF) hospitalizations but not all-cause mortality when started within 14 days of acute myocardial infarction (AMI). Objective To evaluate the association between left ventricular ejection fraction (LVEF), congestion, or both on outcomes and the impact of empagliflozin in reducing HF risk post-MI. Methods In the EMPACT-MI trial, patients were randomized within 14 days of an AMI complicated by either newly reduced LVEF&lt;45%, congestion, or both to empagliflozin 10 mg daily or placebo and followed for a median of 17.9 months. Results Among 6522 patients, the mean baseline LVEF was 41%+9%; 2648 patients (40.6%) presented with LVEF&lt;45% alone, 1483 (22.7%) presented with congestion alone, and 2181 (33.4%) presented with both. Among patients in the placebo arm, multivariable adjusted risk for each 10-point reduction in LVEF included all-cause death or HF hospitalization (hazard ratio [HR] 1.49; 95%CI, 1.31-1.69; P&lt;0.0001), first HF hospitalization (HR, 1.64; 95%CI, 1.37-1.96; P&lt;0.0001), and total HF hospitalizations (rate ratio [RR], 1.89; 95%CI, 1.51-2.36; P&lt;0.0001). Presence of congestion was also associated with a significantly higher risk for each of these outcomes (HR 1.52, 1.94, and RR 2.03, respectively). Empagliflozin reduced the risk for first (HR 0.77, 95%CI 0.60-0.98) and total (RR 0.67, 95%CI 0.50-0.89) HF hospitalization, irrespective of LVEF or congestion or both. The safety profile of empagliflozin was consistent across baseline LVEF and irrespective of congestion status. Conclusions In patients with AMI, severity of LV dysfunction and the presence of congestion was associated with worse outcomes. Empagliflozin reduced first and total HF hospitalizations across the range of LVEF with and without congestion

Effect of empagliflozin on heart failure outcomes after acute myocardial infarction: insights from the EMPACT-MI trial

Background: Empagliflozin reduces the risk of heart failure events in patients with type 2 diabetes at high cardiovascular risk, chronic kidney disease, and in those with prevalent heart failure irrespective of ejection fraction. While EMPACT-MI showed empagliflozin does not reduce the risk of the composite of hospitalization of heart failure and all-cause mortality, the impact of empagliflozin on first and recurrent heart failure events in patients after myocardial infarction is unknown. Methods: EMPACT-MI was a double-blind, randomized, placebo-controlled, event-driven trial that randomized 6522 patients hospitalized for acute myocardial infarction at risk for heart failure based on newly developed left ventricular ejection fraction of &lt;45% and/or signs or symptoms of congestion to receive empagliflozin 10 mg daily or placebo within 14 days of admission. In prespecified secondary analyses, treatment groups were analyzed for heart failure outcomes. Results: Over a median of follow-up of 17.9 months, the risk for first heart failure hospitalization and total heart failure hospitalizations was significantly lower in the empagliflozin compared with the placebo group (118 (3.6%) vs. 153 (4.7%) patients with events, HR 0.77 [95% CI 0.60, 0.98], P=0.031 for first heart failure hospitalization and 148 vs. 207 events, RR 0.67 [95% CI 0.51, 0.89], P=0.006 for total heart failure hospitalizations). Subgroup analysis showed consistency of empagliflozin benefit across clinically relevant patient subgroups for first and total heart failure hospitalizations. Post-discharge need for new use of diuretics, renin-angiotensin modulators, and mineralocorticoid receptor antagonists were less in patients randomized to empagliflozin than placebo (all p&lt;0.05). Conclusions: In patients after acute myocardial infarction with left ventricular dysfunction or congestion, empagliflozin reduced the risk of heart failure

Combined use of Mie–Raman and fluorescence lidar observations for improving aerosol characterization: feasibility experiment

International audienceAbstract. To study the feasibility of a fluorescence lidar for aerosol characterization, the fluorescence channel is added to the LILAS multiwavelength Mie–Raman lidar of Lille University, France. A part of the fluorescence spectrum induced by 355 nm laser radiation is selected by the interference filter of 44 nm bandwidth centered at 466 nm. Such an approach has proved to have high sensitivity, allowing fluorescence signals from weak aerosol layers to be detected and the fluorescence backscattering coefficient from the ratio of fluorescence and nitrogen Raman backscatters to be calculated. Observations were performed during the November 2019–February 2020 period. The fluorescence capacity (ratio of fluorescence to elastic backscattering coefficients), measured under conditions of low relative humidity, varied in a wide range, being the highest for the smoke and the lowest for the dust particles. The results presented also demonstrate that the fluorescence measurements can be used for monitoring the aerosol inside the cloud layers

Spectral homogeneity of human platelets investigated by SERS.

This paper describes a detailed study of the spectral homogeneity of human platelets using Surface-enhanced Raman spectroscopy (SERS). We used a combined approach based on multivariate methods as principal component analysis and pair correlation algorithms to investigate platelets spectral properties. The correlation coefficients for each sample have been calculated, and the average coefficient of determination has been estimated. The high degree of spectral homogeneity inside one probe and between them has been revealed. The prospects of obtained results usage for pathologies based on platelet conformations during cardiovascular diseases have been demonstrated